Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.61 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.61 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | F11 | P03951 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.39 |
| ▸ | CSK | P41240 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3291459 | 0.88 | CA2 (0.63) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL8080450 | 0.82 | HTT (0.41) | TSHR | |
| SCHEMBL890400 | 0.79 | LPL (0.73) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL257753 | 0.78 | LPL (0.58) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL21125600 | 0.77 | LPL (0.60) | LPLLIPGMGLLENPP2 | |
| SCHEMBL2741643 | 0.76 | CHKA (0.41) | CA2CA1TSHR | |
| SCHEMBL257735 | 0.76 | LPL (1.00) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL104626 | 0.76 | ESR1 (0.59) | CA2CA1TSHR | |
| SCHEMBL29955255 | 0.75 | LPL (0.48) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL4737133 | 0.75 | LPL (0.55) | LPLLIPGCA2CA1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180154332-A1 | HIGH PURITY CHROMATOGRAPHIC MATERIALS COMPRISING ION PAIRED-BONDED PHASES FOR SUPERCRITICAL FLUID CHROMATOGRAPHY | WATERS TECHNOLOGIES CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-20180154332-A1 | HIGH PURITY CHROMATOGRAPHIC MATERIALS COMPRISING ION PAIRED-BONDED PHASES FOR SUPERCRITICAL FLUID CHROMATOGRAPHY | WATERS TECHNOLOGIES CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-20170305893-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-10-26 | — | — | US | disclosed |
| US-20170305893-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-10-26 | — | — | US | disclosed |
| US-6673824-B1 | HYPOTENSIVE AGENTS | BRISTOL-MYERS SQUIBB CO. | 2004-01-06 | — | — | US | disclosed |
| US-6107320-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 2000-08-22 | — | — | US | disclosed |
| US-5514696-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1996-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305893-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | DCTPP1, ENPP1, PPA1 | LPL 2499/4885LIPG 3346/4885CA2 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.